1. Anti-infection
  2. Bacterial
  3. RNAIII-inhibiting peptide(TFA)

RNAIII-inhibiting peptide(TFA) 

目录号: HY-P1452A 纯度: 99.19%
COA 产品使用指南

RNAIII-inhibiting peptide(TFA) 是一种有效的 Staphylococcus aureus 多肽抑制剂,在蜂窝组织炎、角膜炎、化脓性关节炎、骨肌炎和乳腺炎等疾病中有功效。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Custom Peptide Synthesis

RNAIII-inhibiting peptide(TFA) Chemical Structure

RNAIII-inhibiting peptide(TFA) Chemical Structure

CAS No. : 2703745-76-8

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
1 mg ¥1000
In-stock
5 mg ¥2100
In-stock
10 mg ¥3100
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 实验参考方法

  • 纯度 & 产品资料

  • 参考文献

生物活性

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.

IC50 & Target

Staphylococcus aureus[1]

体外研究
(In Vitro)

RNAIII-inhibiting peptide(TFA) is a potent inhibitor of Staphylococcus aureus. RNAIII-inhibiting peptide (RIP) inhibits the synthesis of both RNAII and RNAIII, while RAP activates in wild type S. aureus cells. RNAIII-inhibiting peptide (5 μg/106 cells) potently reduces bacterial cell adhesion to HEp2 cells in the absence of serum, but with slight overall reduction the presence of serum. RNAIII-inhibiting peptide inhibits while RAP induces the phosphorylation of TRAP[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

RNAIII-inhibiting peptide (20 mg/kg, i.v.) decreases lethality in mice challenged with S. aureus ATCC 25923, with the lethality rate of 70%, and when combined with cefazolin, imipenem, vancomycin, the rates are 20%, 15% and 10%. RNAIII-inhibiting peptide (20 mg/kg, i.v.) also causes decreased lethality in mice challenged with S. aureus Smith, with the lethality rate of 75%, and the lethality rate decreases to 30%, 10% and 10% when combined with cefazolin, imipenem, vancomycin[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

1027.01

Formula

C47H57F3N10O13

CAS 号
性状

固体

颜色

White to off-white

Sequence

Tyr-Ser-Pro-Trp-Thr-Asn-Phe-NH2

Sequence Shortening

YSPWTNF-NH2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO 中的溶解度 : ≥ 150 mg/mL (146.06 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 100 mg/mL (97.37 mM; 超声助溶)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9737 mL 4.8685 mL 9.7370 mL
5 mM 0.1947 mL 0.9737 mL 1.9474 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
该产品水溶性佳,请具体参考实测 水 / PBS / Saline 中的溶解度数据。
您所需的储备液浓度超过该产品的实测溶解度,如有需要,请与 MCE 中国技术支持联系。
纯度 & 产品资料
参考文献
Animal Administration
[2]

Mice[2]
Mice are randomized to receive intravenously isotonic sodium chloride solution (controls C1 and C2) and 20 mg/kg RNAIII-inhibiting peptide alone or combined with 20 mg/kg cefazolin, 10 mg/kg imipenem, or 10 mg/kg vancomycin. Animals are returned to individual cages and monitored for 7 days. The endpoints of the study are quantitative plasma bacterial evaluation and lethality. For each animal model, toxicity is evaluated on the basis of the presence of any drug-related adverse effects, i.e. local signs of inflammation, anorexia, weight loss, vomiting, diarrhea, fever, and behavioral alterations. In particular, to evaluate the physiological effects of RNAIII-inhibiting peptide, temperature, pulse, blood pressure, respirations and oxygenation are monitored in a supplementary RNAIII-inhibiting peptide-treated group without infection[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

RNAIII-inhibiting peptide(TFA) 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 0.9737 mL 4.8685 mL 9.7370 mL 24.3425 mL
5 mM 0.1947 mL 0.9737 mL 1.9474 mL 4.8685 mL
10 mM 0.0974 mL 0.4869 mL 0.9737 mL 2.4343 mL
15 mM 0.0649 mL 0.3246 mL 0.6491 mL 1.6228 mL
20 mM 0.0487 mL 0.2434 mL 0.4869 mL 1.2171 mL
25 mM 0.0389 mL 0.1947 mL 0.3895 mL 0.9737 mL
30 mM 0.0325 mL 0.1623 mL 0.3246 mL 0.8114 mL
40 mM 0.0243 mL 0.1217 mL 0.2434 mL 0.6086 mL
50 mM 0.0195 mL 0.0974 mL 0.1947 mL 0.4869 mL
60 mM 0.0162 mL 0.0811 mL 0.1623 mL 0.4057 mL
80 mM 0.0122 mL 0.0609 mL 0.1217 mL 0.3043 mL
DMSO 100 mM 0.0097 mL 0.0487 mL 0.0974 mL 0.2434 mL

* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
RNAIII-inhibiting peptide(TFA)
目录号:
HY-P1452A
需求量: